Dietary Intake as a Link between Obesity, Systemic Inflammation, and the Assumption of Multiple Cardiovascular and Antidiabetic Drugs in Renal Transplant Recipients
Table 1
Demographic, anthropometric, and body composition data and the pharmacological of treatment the three groups of kidney transplant recipients divided according to BMI.
NW
OW
OB
Male/female
36/14
20/8
12/6
Age, years
51.5 ± 10.4
48.7 ± 8.5
50.3 ± 10.1
Transplant time, years
7.8 ± 5.1
5.6 ± 4.3
7.9 ± 5.5
Pretransplant BW, Kg
58.2 ± 12.0
66.6 ± 9.4*
74.4 ± 12.1*
Pretransplant BMI, Kg/m²
21.6 ± 2.9
24.2 ± 2.3*
28.2 ± 3.2*∧
BW, Kg
60.5 ± 9.3
74.5 ± 36.7*
87.7 ± 11.7*∧
BMI, Kg/m²
22.5 ± 2.0
27.2 ± 1.3*
33.3 ± 3.2*∧
ΔBW, % of pre-transplant BW
5.6 ± 11.8
13.0 ± 11.5*
19.0 ± 12.6*
TBW, % BW
59.4 ± 6.3
54.8 ± 4.9*
47.9 ± 3.8*∧
ECW, % TBW
45.6 ± 3.9
43.9 ± 4.8
44.2 ± 4.4
FM, % BW
19.9 ± 8.7
25.5 ± 6.4*
35.6 ± 6.7*∧
FFM, % BW
80.0 ± 8.7
74.4 ± 6.4*
64.4 ± 6.7*∧
BCM, Kg
25.4 ± 5.8
30.0 ± 6.1*
29.5 ± 5.7*
TBW/FFM
0.74 ± 0.02
0.73 ± 0.01
0.74 ± 0.02
Systolic blood pressure (mmHg)
126 ± 11
130 ± 14
128 ± 8
Diastolic blood pressure (mmHg)
80 ± 7
81 ± 3
80 ± 5
Cumulative corticosteroid dose (g)
10.8 ± 8.5
8.1 ± 6.4
8.9 ± 8.1
Oral antidiabetic drugs/Insulin therapy (%)
0/4
14/0
0/22
Lipid-lowering therapy (%)
52
71
78
Antihypertensive therapy (%)
100
100
100
BW: body weight; BMI: body mass index; FM: fat mass; FFM: fat-free mass; TBW: total body water; ECW: extracellular water; BCM: body cell mass.
*
versus NW; ∧ versus OW; ANOVA (with Bonferroni’s posttest).
